The How to Design Phase I Vaccine Studies in Europe Webinar is a focused session for sponsors and biotech leaders preparing for clinical entry in a complex and rapidly evolving regulatory landscape. With the right design, early-phase trials not only build the evidence needed for progression, they de-risk your entire development pathway.
Success in Phase I depends on much more than protocol compliance. From defining endpoints and integrating real-world data to selecting the right geography and investigators, early decisions have a long-term impact. Missteps at this stage can delay timelines, raise costs, or compromise data integrity.
Belgium has emerged as a strategic location for early-phase vaccine research, offering sponsors streamlined startup processes, access to controlled human infection models, and expert academic–clinical collaboration. But unlocking those advantages requires a precise, regionally informed approach, something this Webinar will unpack in detail.
Led by experts from P95 and Vaccinopolis, this free, one-hour session offers real-world insights into the design, setup, and execution of early-phase vaccine trials across Europe.
What You’ll Learn at the Webinar
This 60-minute Webinar is tailored to biotech innovators, global health sponsors, and clinical teams advancing vaccine candidates into first-in-human studies. Attendees will gain clarity on how to avoid common pitfalls, leverage epidemiological insight, and make smarter design decisions from the start.
Topics include:
- How to select the most strategic countries and clinical sites for early-phase trials
- The advantages of controlled human infection model studies and how Belgium supports them
- How epidemiological data can shape trial design and improve regulatory confidence
- When and how to use adaptive trial designs or alternative models
- How P95 supports global clients across flexible, modular clinical delivery models
- Whether you’re new to the European landscape or looking to refine your approach, this Webinar provides practical, actionable guidance to strengthen your Phase I strategy.
Planning with Precision: Why Early Decisions Matter
Designing a successful early-phase study starts with clarity on population, endpoints, trial model, and execution strategy. Sponsors that take a proactive, data-driven approach are more likely to hit recruitment targets, align with regulators, and reduce time to the next Phase.
Belgium’s value lies not only in its infrastructure but in its integration of academic, public health, and trial delivery partners. Choosing a location with centralized ethics review and established study pipelines can cut months off your timeline if planned early enough.
This How to Design Phase I Vaccine Studies in Europe Webinar highlights how organizations are incorporating real-world data and local insight into trial planning, from protocol refinement to sample size optimization and regulatory documentation.
The result? Stronger submissions, faster activations, and fewer costly amendments.
Why These Experts and Why Now
This isn’t a generic panel. It’s a practical, experience-driven session led by three professionals who’ve shaped some of Europe’s most significant vaccine trial programs:
- Laurence De Moerlooze, Chief Medical Officer at P95, brings two decades of experience in global vaccine development, spanning regulatory strategy, clinical leadership, and program execution across GSK, Takeda, and Bavarian Nordic.
- Prof. Dr. Pierre Van Damme, Director of Vaccinopolis, has led over 500 vaccine trials and helped establish Belgium as a global hub for early-phase vaccine studies. His decades of academic and field experience have shaped EU and WHO policies alike.
- Kaatje Bollaerts, Epidemiology Business Head at P95, has led major EU public–private initiatives (ADVANCE, DRIVE, VITAL, COVIDRIVE) and specializes in translating epidemiological evidence into smarter trial designs and public health decision-making.
They bring a 360-degree perspective: from design and data to implementation and regulation. They’re hosting this session because early-phase trials in Europe are speeding up, and sponsors need up-to-date, actionable insight from those actively working in the field.
The Advantage of Europe including Belgium for Phase I Vaccine Trials
Thanks to centralized ethics approvals, streamlined regulatory processes, and advanced clinical infrastructure, Belgium enables sponsors to launch early-phase studies with speed and precision. Vaccinopolis is a standout facility: purpose-built for vaccine R&D, and designed to support rapid study cycles while maintaining the highest scientific and ethical standards.
Organizations like P95 allow sponsors to gain access to integrated expertise, from epidemiology and feasibility to study delivery. This synergy makes Belgium not just a compliant trial location, but a strategic one.
If your organization is evaluating Europe for clinical trials, this Webinar will clarify why Belgium should be on your shortlist and how to make the most of its advantages.
Who Should Attend The How to Design Phase I Vaccine Studies in Europe Webinar
- Biotech founders and R&D leads preparing first-in-human studies
- Clinical operations and regulatory affairs professionals
- NGOs and public-private partnerships working on infectious disease vaccines
- Sponsors planning trials in Europe for novel or platform-based vaccines
- Anyone seeking to de-risk and accelerate early-phase clinical work
Secure Your Spot
The How to Design Phase I Vaccine Studies in Europe Webinar is free to attend and includes a live Q&A with all speakers. Don’t miss this opportunity to learn from three of the most experienced voices in vaccine trial design.
Date: Monday, July 28, 2025
Time: 15:30 CET
Format: Online via Xtalks
0 Comments